Thrombolytic Science International, LLC
http://www.tsillc.net/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Thrombolytic Science International, LLC
Rentschler’s New CEO On 2024 Expectations For CDMOs
In Vivo caught up with Benedikt von Braunmühl at the recent BIO-Europe conference in Munich, Germany, to discuss his first six weeks as CEO at Rentschler Biopharma and the biggest trends impacting contract development and manufacturing organizations (CDMO).
Start-Up Previews, December 2012
This Month's Profile Group: Medtech Start-Ups Innovate in Urinary Incontinence features profiles of Floelle, InControl Medical, NexHand, and Solace Therapeutics. Plus these Start-Ups Across Health Care: Ablative Solutions, Epiomed Therapeutics, Halo Healthcare, and Thrombolytic Science International.
Thrombolytic Science International LLC
Thrombolytic Science International LLC’s drug candidate for acute post-stroke therapy is a mutant of pro-urokinase, a natural enzyme found in humans that, like tPA, also activates plasmin. TSI’s modified protein is designed to hold its inert, pro-enzymatic form longer in the bloodstream, enabling it to retain its occlusive clot specificity at higher, therapeutic doses with reduced risk of bleeding.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- TSI
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice